Over the years vaccination has proven to be the most successful health protection program for large populations, to prevent them from acquiring serious infectious and contagious diseases caused by exogenous antigens (ags) such as bacteria and viruses. Protection is generally achieved by an active immunization program, though passive immunization has also been employed, especially in the past, to combat diseases caused by certain bacterial infections (e.g. tetanus, diphtheria, etc.).Most recently, encouraging research data suggests that therapeutic approaches employing vaccination techniques can also be used to correct or deal with mishaps induced by or involving endogenous ags. However, most attempts at employing conventional vaccination techniques to do so have proven less than successful. In the case of cancer, one of the reasons for this is that the presentation of cancer related ags in presently available immunization frameworks is unable to evoke a powerful, specific cancer killing response. Therefore, drug treatments have been required in order to achieve additional beneficial effects.Recently, the Barabas group has developed a new vaccination technique (the third vaccination method, after active and passive immunization) called Modified Vaccination Technique (MVT). In experiments the MVT has been able to prevent-and with equal effectiveness, terminate-mishaps induced by or involving endogenous ags, e.g. in an experimental autoimmune kidney disease called slowly progressive Heymann nephritis (SPHN).The MVT is safe, and is able to initiate a specific immune response in the injected host (provided the injected components are in pure form). The MVT promises to provide the next generation of vaccines for the prevention, treatment, and termination of chronic disorders in humans, such as autoimmune diseases, cancer, and chronic infections.
- Modified vaccination technique